Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

Cao
 
ChiCTR2000029308
RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
99/100 suggested
  • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
CAP-China (Wang et al.)
 
NCT04257656
RCTremdesivirplaceboCOVID-19 severe or criticallylow
158/79 inconclusive
  • inconclusive 23 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias
COALITION II Covid-19 Brazil (Furtado)
 
NCT04321278
RCTazithromycinstandard of careCOVID-19 severe or criticallysome concern
214/183 safety concern
  • inconclusive 26 % decrease in clinical improvement,clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 6 % decrease in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
Okumuş
 
NCT04646109
RCTivermectincontrolCOVID-19 severe or criticallyhigh
30/30 inconclusive
    REMAP-CAP (lopinavir/ritonavir only)
     
    NCT02735707
    RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
    268/377 safety concern
    • statistically significant 17 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
    REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine)
     
    NCT02735707
    RCTLopinavir/ritonavir plus hydroxychloroquinestandard of careCOVID-19 severe or criticallysome concern
    29/377 safety concern
    • suggested 42 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 37 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
    1 study excluded by filtering options (0 RCT / 1 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).